Frontlight ResearchEarly access
CompletedPhase 3
Hydrocorticose and vasopressin in post-resuscitation syndrome
Key facts
- Who runs it
- Assistance Publique Hopitaux De Paris
- Where
- France17 sites in 1 countryChoose a country to see its sites
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 380 people enrolled
- Started
- 18 Jul 2021
- Ended
- 5 Aug 2025
- Type of study
- Interventional
- Record updated
- 28 April 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (19)Hide the full registry criteria
Who can take part
- Adult patients (≥18y)
- Cardiac arrest (in-hospital or out-of-hospital) with sustained ROSC (> 30 minutes) admitted to the ICU
- Post-resuscitation shock defined as arterial hypotension (SAP < 90 mmHg or MAP < 65 mmHg) unresponsive to adequate fluid loading, which occurred within the first 24 hours after ROSC and requiring norepinephrine tartrate/epinephrine continuous infusion at a dose greater or equal to 0.2μg/kg/min for at least 3 hours
- A maximal delay between the start of norepinephrine infusion and randomization of 9 hours
- Informed written consent of a legally authorized close relative, or emergency procedure
Who cannot take part
- inclusion in another randomized trial involving a drug that could interact with either interventional drug
- Previously known adrenal insufficiency
- Limitation of life-sustaining therapies
- Ongoing treatment by any steroids, at a daily dose greater or equal to 7.5mg/d equivalent prednisone for at least 3 weeks
- Evidence for a traumatic or a neurological cause of cardiac arrest
- Hypersensitivity to argipressin and to its excipients
- Hypersensitivity to hydrocortisone and to its excipients
- In-ICU cardiac arrest
- Shock due to uncontrolled haemorrhage
- Gastrointestinal bleeding in the past 6 weeks
- Legal protection (i.e. incompetence to provide consent, guardianship, curator or incarceration)
- No affiliation with the French health care system
- Ongoing extra-corporeal circulatory assistance
- Pregnant or breastfeeding women
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
to demonstrate the superiority of AVP and hydrocortisone compared with placebo regarding day-30 survival and neurological recovery in post-cardiac arrest patients with hemodynamic failure.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- HYVAPRESS. HYdrocortisone and VAsopressine in Post-RESuscitation Syndrome
- Publications
- Hydrocortisone and arginine vasopressin in post-resuscitation shock: the HYVAPRESS trial.Resuscitation plus, 2025
- Record updated
- 28 April 2025